These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 358897)

  • 1. Potential applications of liposomes to therapy.
    Ryman BE; Jewkes RF; Jeyasingh K; Osborne MP; Patel HM; Richardson VJ; Tattersall MH; Tyrrell DA
    Ann N Y Acad Sci; 1978; 308():281-307. PubMed ID: 358897
    [No Abstract]   [Full Text] [Related]  

  • 2. [Therapeutics future of liposomes (author's transl)].
    Portal A; Duron F; Aubert P
    Nouv Presse Med; 1979 May; 8(21):1749-52. PubMed ID: 286979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of liposomes in treating type II glycogenosis.
    Tyrrell DA; Ryman BE; Keeton BR; Dubowitz V
    Br Med J; 1976 Jul; 2(6027):88. PubMed ID: 1064464
    [No Abstract]   [Full Text] [Related]  

  • 4. Enzyme replacement in Pompe disease with an alpha-glucosidase-low density lipoprotein complex.
    Williams JC; Murray AK
    Birth Defects Orig Artic Ser; 1980; 16(1):415-23. PubMed ID: 7004520
    [No Abstract]   [Full Text] [Related]  

  • 5. Drug-carrier potential of liposomes in cancer chemotherapy.
    Gregoriadis G; Wills EJ; Swain CP; Tavill AS
    Lancet; 1974 Jun; 1(7870):1313-6. PubMed ID: 4134296
    [No Abstract]   [Full Text] [Related]  

  • 6. First treatment for Pompe disease.
    FDA Consum; 2006; 40(4):3. PubMed ID: 17245826
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical prospects for liposomes.
    Yatvin MB; Lelkes PI
    Med Phys; 1982; 9(2):149-75. PubMed ID: 7045623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Desensitisation of the youngest patient with Pompe disease in response to alglucosidase alfa.
    Karagol IH; Bakirtas A; Yilmaz O; Topal E; Kucukcongar A; Ezgu FS; Demirsoy MS; Turktas I
    Allergol Immunopathol (Madr); 2014; 42(4):372-5. PubMed ID: 23769736
    [No Abstract]   [Full Text] [Related]  

  • 9. Effects of entrapment in liposomes on the distribution, degradation and effectiveness of methotrexate in vivo.
    Kimelberg HK; Atchison ML
    Ann N Y Acad Sci; 1978; 308():395-410. PubMed ID: 100041
    [No Abstract]   [Full Text] [Related]  

  • 10. Alglucosidase alfa and Pompe disease: still going strong?
    Lipinski SE
    Mol Genet Metab; 2012 Nov; 107(3):245-6. PubMed ID: 23034445
    [No Abstract]   [Full Text] [Related]  

  • 11. Pompe disease in infants and children.
    Kishnani PS; Howell RR
    J Pediatr; 2004 May; 144(5 Suppl):S35-43. PubMed ID: 15126982
    [No Abstract]   [Full Text] [Related]  

  • 12. Cognitive outcome of patients with classic infantile Pompe disease receiving enzyme therapy.
    Spiridigliozzi GA; Heller JH; Kishnani PS; Van der Ploeg AT; Ebbink BJ; Aarsen FK; van Gelder CM; Van den Hout JM
    Neurology; 2013 Mar; 80(12):1173. PubMed ID: 23509050
    [No Abstract]   [Full Text] [Related]  

  • 13. [Oral administration of insulin by means of liposomes in animal experiments (author's transl)].
    Tragl KH; Pohl A; Kinast H
    Wien Klin Wochenschr; 1979 Jun; 91(13):448-51. PubMed ID: 463043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDA balks at Myozyme scale-up.
    Mack G
    Nat Biotechnol; 2008 Jun; 26(6):592. PubMed ID: 18536660
    [No Abstract]   [Full Text] [Related]  

  • 15. Low-cost oral delivery of protein drugs bioencapsulated in plant cells.
    Kwon KC; Daniell H
    Plant Biotechnol J; 2015 Oct; 13(8):1017-22. PubMed ID: 26333301
    [No Abstract]   [Full Text] [Related]  

  • 16. When should we start enzyme replacement therapy for infantile Pompe disease with severe cardiomyopathy?
    Bonilla-Palomas JL; Gámez-López AL; Tejero-Hernández MA; Tejero-Mateo I; López-López J
    Rev Esp Cardiol (Engl Ed); 2012 Jan; 65(1):100-2. PubMed ID: 21715078
    [No Abstract]   [Full Text] [Related]  

  • 17. Elimination of antibodies to recombinant enzyme in Pompe's disease.
    Mendelsohn NJ; Messinger YH; Rosenberg AS; Kishnani PS
    N Engl J Med; 2009 Jan; 360(2):194-5. PubMed ID: 19129538
    [No Abstract]   [Full Text] [Related]  

  • 18. Pompe disease therapy presents coverage challenge.
    Morrow T
    Manag Care; 2006 Jun; 15(6):63-4. PubMed ID: 16838889
    [No Abstract]   [Full Text] [Related]  

  • 19. Enzyme replacement for infantile Pompe disease: the first step toward a cure.
    Wagner KR
    Neurology; 2007 Jan; 68(2):88-9. PubMed ID: 17210887
    [No Abstract]   [Full Text] [Related]  

  • 20. Potential of liposomes as drug-carriers in cancer chemotherapy: a review.
    Kaye SB; Richardson VJ
    Cancer Chemother Pharmacol; 1979; 3(2):81-5. PubMed ID: 389479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.